AbbVie Shares Plunge 10.77% in Four Days Trading Volume Ranks 39th

AbbVie (ABBV) shares fell 7.28% on Thursday, marking the fourth consecutive day of decline, with a total decrease of 10.77% over the past four days. The company's trading volume reached $25.78 billion, ranking 39th in the market for the day.

AbbVie has revised its 2025 adjusted profit forecast due to anticipated acquisition-related expenses of $248 million. This adjustment reflects the company's expectation of increased costs associated with recent acquisitions, which will impact its financial performance for the year.

The drugmaker has also lowered its earnings guidance for the first quarter and fiscal year 2025. This revision is attributed to expenses related to intellectual property research and development (IPR&D) and milestone payments. The adjusted diluted earnings per share guidance for 2025, previously announced on January 31, 2025, did not account for the impact of these acquired IPR&D and milestone expenses.

Additionally, AbbVie has announced that it will host a conference call to discuss its first-quarter 2025 financial results on April 25, 2025, before the market opens. This call will provide investors with an opportunity to gain insights into the company's performance and outlook for the remainder of the year.